Saturday, October 05, 2024 12:31:26 PM
LC,
That is correct, but you reminded me of something quite fascinating that I did officially predict about the great Dr. Liau…
Dr. Steinman was award the Nobel Prize for discovering the dendritic cell. In 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology or Medicine for their pioneering work in cancer therapy through the discovery of immune checkpoint inhibitors.
Today, Dr. Linda Liau and Dr. Pawel Kalinski are combining dendritic cell technology with checkpoint blockade technology to reach new levels of efficacy and healing for patients! UCLA and Roswell are studying how these two Nobel Prize-winning discoveries can be combined to treat multiple distinct cancers!
These combo trials are relatively new and have only recently reached PII clinical investigation.
If the researchers who discovered these two technologies were awarded the Nobel Prize, why wouldn’t the researchers who discovered the combo be considered for the Nobel Prize?
Recently, we commemorated the loss of the great Dr. Ralph Steinman 13 years ago on September 30th.
“We know he will live on through his scientific contributions.”
Dr. Steinman’s legacy is changing the field of cancer immunotherapy today, and his invaluable Nobel Prize-winning work lives on at UCLA, King’s College and Roswell Park, among other cutting-edge institutions.
The recent evolution of dendritic cell technology has been vast, and Dr. Steinman’s prophetic words foreshadowed the future and DCVax-L. In the last 3 minutes of the YouTube video, Dr. Steinman describes the “first generation of this approach” which used only ONE single antigen. Consider that DCVax-L can present HUNDREDS of distinct antigens today!
That is correct, but you reminded me of something quite fascinating that I did officially predict about the great Dr. Liau…
Dr. Steinman was award the Nobel Prize for discovering the dendritic cell. In 2018, James P. Allison and Tasuku Honjo were awarded the Nobel Prize in Physiology or Medicine for their pioneering work in cancer therapy through the discovery of immune checkpoint inhibitors.
Today, Dr. Linda Liau and Dr. Pawel Kalinski are combining dendritic cell technology with checkpoint blockade technology to reach new levels of efficacy and healing for patients! UCLA and Roswell are studying how these two Nobel Prize-winning discoveries can be combined to treat multiple distinct cancers!
These combo trials are relatively new and have only recently reached PII clinical investigation.
If the researchers who discovered these two technologies were awarded the Nobel Prize, why wouldn’t the researchers who discovered the combo be considered for the Nobel Prize?
Recently, we commemorated the loss of the great Dr. Ralph Steinman 13 years ago on September 30th.
“We know he will live on through his scientific contributions.”
Dr. Steinman’s legacy is changing the field of cancer immunotherapy today, and his invaluable Nobel Prize-winning work lives on at UCLA, King’s College and Roswell Park, among other cutting-edge institutions.
The recent evolution of dendritic cell technology has been vast, and Dr. Steinman’s prophetic words foreshadowed the future and DCVax-L. In the last 3 minutes of the YouTube video, Dr. Steinman describes the “first generation of this approach” which used only ONE single antigen. Consider that DCVax-L can present HUNDREDS of distinct antigens today!
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
